EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N Sternberg, Ian D Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H Barrios, Pamela Salman, Oleg A Gladkov, Alexander Kavina, Juan J Zarbá, Mei Chen und 4 weitere

Journal of Clinical Oncology · 10.04.2023 · 41 (11) · 1957-1964

DOI: 10.1200/jco.22.02622 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2023. Verfasst von Cora N Sternberg und 15 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australi…. Die Arbeit wurde bisher 19-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Patients and Methods Adult patients with measurable, locally advanced, and/or metastatic RCC were randomly assigned 2:1 to receive oral pazopanib or placebo. The primary end point was progression-free survival (PFS). Secondary end points included overall survival, tumor response rate (Response Evaluation Criteria in Solid Tumors), and safety. Radiographic assessments of tumors were independently reviewed.

Results

Of 435 patients enrolled, 233 were treatment naive (54%) and 202 were cytokine pretreated (46%). PFS was significantly prolonged with pazopanib compared with placebo in the overall study population (median, PFS 9.2 v 4.2 months; hazard ratio [HR], 0.46; 95% CI, 0.34 to 0.62; P < .0001), the treatment-naive subpopulation (median PFS 11.1 v 2.8 months; HR, 0.40; 95% CI, 0.27 to 0.60; P < .0001), and the cytokine-pretreated subpopulation (median PFS, 7.4 v 4.2 months; HR, 0.54; 95% CI, 0.35 to 0.84; P < .001). The objective response rate was 30% with pazopanib compared with 3% with placebo ( P < .001). The median duration of response was longer than 1 year. The most common adverse events were diarrhea, hypertension, hair color changes, nausea, anorexia, and vomiting. There was no evidence of clinically important differences in quality of life for pazopanib versus placebo.

Conclusion

Pazopanib demonstrated significant improvement in PFS and tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC.

Autor:innen und Institutionen

  • From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Depa…

Zitieren

APA

Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., Zarbá, J. J., Chen, M., McCann, L., Pandite, L., Roychowdhury, D. F., & Hawkins, R. E. (2023). Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology, 41(11), 1957-1964. https://doi.org/10.1200/jco.22.02622

Vancouver

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 2023;41(11):1957-1964. doi:10.1200/jco.22.02622

BibTeX
@article{Sternberg2023,
  author = {Sternberg, Cora N and Davis, Ian D and Mardiak, Jozef and Szczylik, Cezary and Lee, Eunsik and Wagstaff, John and Barrios, Carlos H and Salman, Pamela and Gladkov, Oleg A and Kavina, Alexander and Zarbá, Juan J and Chen, Mei and McCann, Lauren and Pandite, Lini and Roychowdhury, Debasish F and Hawkins, Robert E},
  title = {Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {11},
  pages = {1957--1964},
  doi = {10.1200/jco.22.02622}
}
Kostenlos starten →